Financial Performance - Net loss for Q3 fiscal 2024 was ($2.5 million), a significant improvement from a net loss of ($11.9 million) in Q3 fiscal 2023[6]. - Total revenue for Q3 fiscal 2024 was $4.4 million, down from $6.1 million in Q3 fiscal 2023, attributed to client non-renewals offset by new SaaS contracts[4]. - SaaS revenue for Q3 fiscal 2024 was $2.9 million, representing 66% of total revenue, compared to $3.9 million (64%) in Q3 fiscal 2023[5]. - Adjusted EBITDA for Q3 fiscal 2024 was a loss of ($0.3 million), compared to a gain of $0.4 million in Q3 fiscal 2023[8]. - Total revenues for the three months ended October 31, 2024, were $4,419,000, a decrease of 28% compared to $6,133,000 for the same period in 2023[21]. - Net loss for the nine months ended October 31, 2024, was $8,018,000, compared to a net loss of $17,327,000 for the same period in 2023, representing a 54% improvement[23]. - For the three months ended October 31, 2024, the net loss was $2,476,000, compared to a net loss of $11,911,000 for the same period in 2023, representing an improvement of 79%[24]. - The company’s total adjusted EBITDA for the nine months ended October 31, 2024, was $(1,331,000), an improvement from $(1,817,000) in the same period last year[24]. Cash and Liquidity - Cash and cash equivalents as of October 31, 2024, were $0.8 million, a decrease from $3.2 million as of January 31, 2024[7]. - Cash and cash equivalents decreased to $754,000 as of October 31, 2024, down from $3,190,000 at the beginning of the period[22]. - The Company had no outstanding balance on its revolving credit facility as of October 31, 2024, compared to $1.5 million as of January 31, 2024[7]. Operating Expenses and Cost Management - The strategic restructuring at the end of fiscal 2023 resulted in reductions in cost of sales, SG&A, and R&D expenses of $1.9 million and $5.3 million, respectively[6]. - Total operating expenses for the nine months ended October 31, 2024, were $19,670,000, down from $35,776,000 for the same period in 2023, a reduction of 45%[21]. - The company incurred $1,134,000 in research and development expenses for the three months ended October 31, 2024, compared to $1,304,000 for the same period in 2023[21]. - The company incurred interest expenses of $496,000 for the three months ended October 31, 2024, compared to $266,000 in the prior year, reflecting an increase of 86%[24]. - Depreciation and amortization expenses were $1,187,000 for the three months ended October 31, 2024, slightly up from $1,105,000 in the same period last year[24]. - The company reported acquisition-related costs of $16,000 for the three months ended October 31, 2024, down from $213,000 in the same period last year[24]. - Restructuring charges amounted to $749,000 for the three months ended October 31, 2023, with no charges reported in the current period[24]. Revenue and Contract Value - Total Booked SaaS Annual Contract Value (ACV) as of October 31, 2024, was $14.1 million, down from $15.0 million as of January 31, 2024[9]. - The Company expects to achieve an adjusted EBITDA breakeven run rate of $15.5 million in implemented SaaS ARR by the first half of fiscal 2025[11]. Balance Sheet and Equity - The company has a total stockholders' equity of $13,914,000 as of October 31, 2024, down from $18,814,000 as of January 31, 2024[22]. - Total liabilities as of October 31, 2024, were $22,052,000, a slight decrease from $22,921,000 as of January 31, 2024[22]. - Accounts receivable decreased to $2,824,000 as of October 31, 2024, from $4,237,000 as of January 31, 2024[22]. Goodwill and Impairment - The impairment of goodwill was recorded at $9,813,000 for the nine months ended October 31, 2023, with no impairment recorded in the current period[24].

Core Insights - Streamline Health Solutions, Inc. reported a net loss of $2.5 million in Q3 fiscal 2024, a significant improvement from a net loss of $11.9 million in Q3 fiscal 2023 [1][5] - The company reiterated its expectation for a $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate and has accelerated this expectation to the first half of fiscal 2025 [1][10] Financial Performance - Total revenue for Q3 fiscal 2024 was $4.4 million, down from $6.1 million in Q3 fiscal 2023. For the nine months ended October 31, 2024, revenue totaled $13.2 million compared to $17.2 million in the same period of fiscal 2023 [3][21] - SaaS revenue for Q3 fiscal 2024 was $2.9 million, representing 66% of total revenue, compared to $3.9 million (64% of total revenue) in Q3 fiscal 2023. For the nine months ended October 31, 2024, SaaS revenue was $8.7 million (66% of total revenue) compared to $10.6 million (62% of total revenue) in the same period of fiscal 2023 [4][21] Cost Management - The net loss for the nine months ended October 31, 2024, was $8.0 million, down from $17.3 million in the same period of fiscal 2023. This improvement was attributed to lower total revenues and higher interest expenses, offset by reductions in cost of sales, SG&A, and R&D expenses totaling $1.9 million and $5.3 million, respectively [5][7] - Adjusted EBITDA for Q3 fiscal 2024 was a loss of $0.3 million, compared to a gain of $0.4 million in Q3 fiscal 2023. For the nine months ended October 31, 2024, adjusted EBITDA was a loss of $1.3 million, an improvement from a loss of $1.8 million in the same period of fiscal 2023 [7][10] Cash Position - As of October 31, 2024, cash and cash equivalents were $0.8 million, down from $3.2 million as of January 31, 2024. The company had no outstanding balance on its revolving credit facility as of October 31, 2024, compared to $1.5 million as of January 31, 2024 [6][21] - The company received a $1.0 million draw from its revolving line of credit on November 20, 2024 [6] Strategic Outlook - The company’s total Booked SaaS Annual Contract Value (ACV) was $14.1 million as of October 31, 2024, down from $15.0 million as of January 31, 2024. However, $12.0 million of the Booked SaaS ACV was implemented as of October 31, 2024, compared to $11.1 million as of January 31, 2024 [8][10] - Management expressed optimism about expanding client relationships and improving financial performance, leading to an accelerated timeline for achieving adjusted EBITDA breakeven [11]

Core Insights - Streamline Health Solutions, Inc. has signed a new contract for its eValuator technology with a 900-bed health system in northern Texas, marking the fourth Texas health system to adopt this solution, indicating the company's expanding presence in the region [1][2][3] - The eValuator technology utilizes AI-enhanced pre-bill code auditing to help healthcare providers accurately capture and bill for services, thereby improving financial performance and reducing denial rates [2][3] - The CEO of Streamline Health emphasized the importance of Texas in the healthcare landscape and expressed pride in expanding the company's footprint in the state, highlighting the commitment to ensuring accurate payments for healthcare services [3] Company Overview - Streamline Health Solutions, Inc. focuses on enabling healthcare organizations to address revenue leakage and enhance financial performance through integrated solutions, technology-enabled services, and analytics [3] - The company's offerings are designed to drive compliant revenue, ultimately leading to improved financial outcomes across healthcare enterprises [3]

Core Insights - Streamline Health Solutions, Inc. has expanded its relationship with a leading academic medical center in Florida to include the eValuator Quality Module, which is expected to increase SaaS revenues from this client by 20% [1][2]. Company Overview - Streamline Health is at the forefront of improving hospital financial performance through pre-bill technology solutions, specifically with its AI-powered eValuator platform that analyzes 100% of encounters in real-time [2]. - The eValuator Quality Module allows health systems to assess the risk score of individual claims and their impact on overall quality measurement in real-time, replacing manual risk scoring practices [2][3]. - The company aims to empower clients to enhance patient care while ensuring accurate reimbursement through real-time insights into risk scoring and quality metrics [3].

ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) --  Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its relationship with an existing eValuator client include the recently released eValuator Quality Module. Streamline expects that this module will increase the SaaS revenues from its eValuator relationship with this client by 25%. Streamline Health is leading an industry movement to imp ...

Atlanta, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has debuted a new quality module for eValuator and successfully implemented that module at an existing eValuator client. Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. eValuator's AI-enhanced pre-bill code auditing ens ...

ATLANTA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. ("Streamline" or the "Company") (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, today announced that it will proceed with a 1-for-15 reverse stock split (the "Reverse Stock Split") of its outstanding shares of Common Stock (the "Common Stock") following approval by its Board of Directors. The 1-for-15 ratio is within the range approved by the Company's stockholders ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its ch ...

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q2 2024 Earnings Conference Call September 12, 2024 9:00 AM ET Company Participants Jacob Goldberger - Vice President, Finance Ben Stilwill - President & Chief Executive Officer B.J. Reeves - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Michael Potter - Monarch Capital Operator Greetings. Welcome to Streamline Health Solutions Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mo ...

Exhibit 99.1 Streamline Health® Reports Fiscal Second Quarter 2024 Financial Results ● Net loss of ($2.8 million) during the second quarter of fiscal 2024 compared to a net loss of ($2.5 million) during the second quarter of fiscal 2023 ● Adjusted EBITDA improved to a loss of ($0.3 million) for the second quarter of fiscal 2024 compared to a loss of ($0.9 million) for the second quarter of fiscal 2023 ● Company reiterated $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate expectation ● Co ...